Combination chemotherapy with consecutive low-dose cisplatin with ifosfamide and epirubicin (CLD-IEP) in uterine sarcoma

10057 Background: To evaluate the efficacy and toxicity of CLD-IEP for patients (pts) with sarcoma uteri. Methods: Eligible criteria were: a histologic proof of advanced or recurrent sarcoma uteri; measurable lesions; age between 18 and 80 yrs; WHO PS 0–3; WBC = 3,000/μL; platelet count = 100,000/μL; hemoglobin level = 9 g/dL; adequate liver function; C-Cr = 40 mL/min; no lung, heart, or brain disease; no previous neoplastic disease; no prior chemotherapy; and informed consent. The CLD-IEP regimen was ifosfamide 700 mg/m2 infused over 2 hrs days 1 through 3; epirubicin 50 mg/m2 bolus day 5; and cisplatin 15 mg/m2 infused over 4 hrs days 1 through 5. The treatment was repeated at 4-week intervals. Results: To date, forty eligible pts (16 leiomyosarcoma [LMS], 4 endometrial stromal sarcoma, and 20 carcinosarcoma) were enrolled in this study and all pts were assessable for response, toxicity, and survival. The median age was 52 yrs (range, 28–77). Thirteen pts received CLD-IEP in the neoadjuvant setting. Nin...